INFINITY PHARMACEUTICALS, INC. INFI Cash Flow

Infinity pharmaceuticals, inc. (INFI)

CashFlow / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11
Operating activities
Net loss
-10,886	-11,382	-11,417	-10,514	-13,744	-8,220	13,381	-6,963	-9,451	-7,296	-7,105	-16,954	-10,475	-22,930	-19,498	52,991	-40,664	-39,190	42,544	-38,428	-93,302	-40,342	103,216	-38,024	-42,266	-32,925	-33,938	-32,591	-27,326	-46,985	18,403	-14,660	-10,722	-14,061	-11,944	-11,731	-2,306
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation
120	137	64	8	10	30	45	53	63	70	261	692	692	852	1,180	693	693	735	589	614	354	406	447	452	468	487	465	429	442	386	404	407	446	466	471	584	578
Stock-based compensation, including 401(k) match
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,751	2,965	2,932	2,947	3,744	2,820	3,259	2,084	3,992	2,729	1,767	1,811	1,504	1,290	1,351	1,406	1,394
Stock-based compensation
360	460	427	563	683	864	856	845	883	1,581	1,587	1,997	1,807	3,397	2,789	3,813	3,715	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash royalty revenue
226	163	180	136	76	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash interest expense
38	75	1,125	1,096	304	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash related party interest expense
534	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash interest expense
-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash interest expense on long-term debt due to Purdue entities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	1,347	-120	681	-	-	-	-
Non-cash interest expense on Due to Takeda amount
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	53	52	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of loan commitment asset
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	647	1,034	4,538	2,938	1,139	-	-	-	-	-	-	-	-	289	433	433	433
Net amortization of premium/discount on available-for-sale securities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-72	-129	-165	-371	-592	-631	-649	-528	-393	-584	-428	-349	-292	-202	-201	-245	-267
Other, net
24	63	108	22	23	21	17	-101	-75	22	11	-1	-7	139	-23	-58	-56	344	-42	-139	-1	-58	-26	-29	30	-	-	-	-102	-5	-11	-14	-16	-14	-24	-11	-23
Changes in operating assets and liabilities:
Unbilled accounts receivable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-237	19	-	-	-	-
Unbilled accounts receivable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	548
Prepaid expenses and other assets
341	-452	417	-1,776	2,567	-90	-312	2	471	-6,113	5,394	-2,322	-4,069	-4,554	-482	-4,436	4,264	3,162	-1,604	2,430	-4,921	1,131	-1,206	-481	1,050	6,365	-441	-114	1,474	-163	373	-809	1,636	-623	22	460	-215
Operating lease right-of-use assets
-56	-92	-31	-241	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accounts payable, accrued expenses and other liabilities
-1,275	1,290	568	-46	-262	1,615	432	1,140	-354	726	-5,603	353	-13,275	-6,473	-18,542	11,634	-2,327	1,681	7,066	8,805	-5,778	-5,707	11,295	764	463	-1,222	2,631	3,585	-1,429	-5,717	-5,834	3,249	-4,093	3,077	4,618	1,752	-8,088
Operating lease liability
-133	264	79	-118	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Due to Takeda
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-6,667	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Due to Takeda
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-6,667	-	-	-	-	-	-	-	-	-	-	-	-
Deferred revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-9,468	-9,255	-9,078	39,256	-4,880	-4,364	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred rent
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-141	173	-	-	-	707	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-20,968	-35,088	-46,427	-51,873	82,768	-34,918	-31,845	-99,658	-46,980	238,239	-29,989	-43,555	-	-	-	-25,300	-	-	-	-	-	-	-	-
Deferred revenue from Purdue entities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-46,555	5,352	2,316	-1,054	-1,409	-1,211	-1,107
Net cash used in operating activities
-11,777	-8,875	-9,819	-7,161	-15,675	16,358	-6,991	-4,826	-9,255	1,208	-11,037	-9,707	-17,175	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-30,402	-2,431	-11,215	-8,554	-6,924	-8,492	-9,139
Investing activities
Purchases of property and equipment
18	767	1,336	191	33	0	0	0	0	-	-	-	-	0	23	368	270	1,010	1,447	2,857	1,112	998	93	95	176	408	375	684	287	634	336	95	236	720	186	305	331
Purchases of available-for-sale securities
19,732	4,183	15,920	9,182	12,579	0	9,942	0	5,744	1,998	21,987	0	0	14,013	12,798	5,369	34,323	57,016	0	64,440	0	0	9,253	0	12,536	19,165	49,734	89,036	91,829	46,646	79,271	42,774	11,807	58,624	32,788	26,109	33,067
Proceeds from maturities of available-for-sale securities
20,180	14,450	6,000	6,500	5,000	0	0	17,260	11,530	1,000	0	0	18,000	9,775	23,024	48,491	12,110	25,674	38,582	10,011	15,248	32,293	6,965	60,574	41,172	69,550	73,813	67,390	40,340	31,683	27,304	32,704	21,829	18,877	45,218	30,515	42,543
Proceeds from sales of available-for-sale securities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	1,289
Net cash provided by (used in) investing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-3,244	11,349	54,707	-22,483	-32,352	37,599	-57,286	14,136	31,295	-2,381	60,479	28,460	-	-	-	-51,776	-	-	-	-	-	-	-	-
Net cash provided by (used in) investing activities
430	9,500	-11,256	-2,873	-7,612	0	-9,942	17,260	5,786	-265	-22,013	0	18,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-52,303	-3,884	9,786	-40,467	12,244	4,101	10,434
Financing activities
Proceeds from sale of future royalties to a related party, net
19,572	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from sale of future royalties, net
0	0	0	0	27,618	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from common stock sales facility, net of issuance costs
-	-	-	-	-	0	-25	5,947	3,408	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	135	9
Proceeds from issuances of common stock, net
-	-	-	-	-	42	9	209	29	84	-8	70	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Repayment of note payable
-	-	-	-	-	-	-	-	-4,000	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payments on financing obligation
-	-	-	-	-	-	-	-	-	0	74	110	108	105	105	103	102	100	99	37	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuances of common stock related to stock incentive plans and awards
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	43	-	95	531	1,162	908	913	108	1,952	754	917	1,152	2,476	-	-	-	-	-	-	-	-
Restricted cash
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by (used in) financing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-235	-105	316	-59	470	-4	693	1,162	1,833	-117	55	1,952	-	-	-	2,476	-	-	-	-	-	-	-	-
Proceeds from issuances of common stock related to stock incentive plans
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	694	-	-	-	-
Capital lease payments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	2	1
Net cash provided by financing activities
19,572	47	38	27	27,618	42	-16	6,156	-563	84	-82	-40	-108	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	115,971	2,504	694	50,127	309	133	8
Net increase in cash, cash equivalents and restricted cash
8,225	672	-21,037	-10,007	4,331	16,400	-16,949	18,590	-4,032	1,027	-33,132	-9,747	717	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Reconciliation of cash, cash equivalents, and restricted cash to the consolidated balance sheets
Net decrease in cash and cash equivalents
-	-	-	-	-	-	-	-	-	-	-	-	-	-24,447	-23,844	8,596	-74,415	50,886	2,677	-88,438	-84,360	-13,852	235,741	30,545	-13,143	14,636	-1,770	-45,894	-74,600	122,825	33,266	-3,811	-735	1,106	5,629	-4,258	1,303
Supplemental schedule of noncash activities
Cash paid for interest
-	-	-	-	-	-	-	-	-	-	-	300	302	304	305	307	309	310	312	99	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Supplemental schedule of noncash activities
Loan commitment asset
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-1,500	0	11,350	-	-	-	-	-	-	-	-	-	-	-	-
Facility fee
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-1,500	0	3,000	-	-	-	-	-	-	-	-	-	-	-	-
Warrants issued
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	8,350	-	-	-	-	-	-	-	-	-	-	-	-
Property and equipment in accounts payable and accrued expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	101	-124	-392	214	367	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Issuance of common stock for repayment of note payable, including interest
-	-	-	-	-	0	0	0	2,301	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Issuance of common stock for compensation
444	0	0	0	0	0	0	0	493	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Increase in property and equipment for amount paid by landlord
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	219	2,214	2,626	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-